BMRN Earnings Prediction
The chart below shows how BMRN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BMRN sees a +0.91% change in stock price 10 days leading up to the earnings, and a -1.40% change 10 days following the report. On the earnings day itself, the stock moves by +0.06%. This data can give you a slight idea of what to expect for the next quarter's release.
BMRN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
745.74M
28.28%
4.73%
Gross Margin
74.06%
-2.35%
-7.04%
Operating Margin
21.11%
378.68%
-5.76%
Net Margin
14.22%
104.60%
-5.51%
EPS
0.55
161.90%
0.00%
No Data Available
BMRN Earnings Analysis
BioMarin Pharmaceuticals Inc Corporation (BMRN.O) Earnings Conference Call
Positive
Revenue Surge 28%: Revenue reached $746 million, marking a robust 28% increase compared to the same period in 2023.
Achondroplasia Revenue Surge: V O X Z O G O experienced a 50% revenue growth for the treatment of achondroplasia, supported by a significant level of new patient starts.
Enzyme Therapies Revenue Growth: The Enzyme Therapies segment saw a 27% revenue growth in Q3 and 13% year-to-date growth.
Earnings Per Share Surge: Q3 GAAP diluted earnings per share increased 162% over Q3 last year to $0.55, while non-GAAP diluted earnings per share nearly doubled compared to Q3 2023, totaling $0.91.
Long-Term Revenue Guidance: The company reaffirmed its long-term revenue guidance, targeting approximately $4 billion in total revenues by 2027, reaching 40% non-GAAP operating margins starting in 2026.
Negative
Achondroplasia Treatment Revenue Surge: Revenue growth was driven by a 50% increase in V O X Z O G O for the treatment of achondroplasia, but this growth was supported by a significant level of new patient starts driven by increased penetration in the U.S. and new geographies that leveraged our Board, geographic footprint and capabilities.
Expanded Indication Benefits: The growth is also being driven by our expanded indication into infants and the increasing evidence of V O X Z O G O's benefits to the health of patients beyond height.
Global Launch Momentum: The global launch of V O X Z O G O for achondroplasia continues to gain momentum worldwide, we have confidence in our sustained leadership across our Skeletal Conditions franchise over the long-term.
Achondroplasia Market Leadership: Our proven capabilities of diagnosing, treating, facilitating market access and building the achondroplasia therapeutic area provide BioMarin the unique ability to sustainably lead this global market.
Achondroplasia Market Confidence: The five key reasons supporting our confidence in growing and maintaining the achondroplasia market are first, a potential five-year commercial lead including the largest database in achondroplasia of long-term durable efficacy in greater than 6,000 patient years of safety and an emerging dataset on benefits beyond height including quality of life.
BMRN FAQs
How does BMRN typically perform around its earnings report dates?
Is BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BMRN Earning Call Sentiment
BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BMRN.O
-0.08%Positive
The earnings report highlights strong financial performance with a 28% revenue increase, raised guidance, and significant progress in strategic priorities. Despite some supply chain and competitive pressures, the Q&A section reveals confidence in R&D and IP strategies. The raised guidance and strong EPS growth indicate optimism. Settling convertible debt is a positive shareholder move. Overall, the positive financial metrics and strategic progress outweigh concerns, suggesting a stock price increase.
